Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roopen Patel

Allergy & Immunology Charlotte, NC Medical Doctor

NPI 1528145224 CMS profile 1260354

2600 E 7Th St, Unit A, Charlotte, NC 28204

Open in the dashboard

General payments

$256,740

998 records reported · program years 2019–2025

Research payments

$8,534

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$133,784 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Roopen Patel of Charlotte, NC is reported in the CMS Open Payments database as having received $256,740 across 998 general payments and $8,534 in research payments paid to them. Separately, studies naming them as principal investigator received $133,784 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $77,692 212
2024 General $49,244 142
2023 General $28,087 123
2022 General $28,630 132
2021 General $39,954 127
2020 General $11,753 97
2019 General $21,379 165
2019 Research $8,534 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roopen Patel
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Roopen Patel were reported at $77,692. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Roopen Patel Allergy & Immunology median Middle half National median
2019 $21,379 $594 $163–$1,512 $163
2020 $11,753 $426 $106–$1,233 $114
2021 $39,954 $638 $157–$1,708 $132
2022 $28,630 $790 $205–$1,961 $149
2023 $28,087 $852 $220–$2,147 $160
2024 $49,244 $865 $203–$2,267 $164
2025 $77,692 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $80,915 177 payments
  2. Genzyme Corporation $67,585 109 payments
  3. GlaxoSmithKline, LLC. $46,821 147 payments
  4. Lilly USA, LLC $27,600 22 payments
  5. AstraZeneca Pharmaceuticals LP $17,504 175 payments
  6. Amgen Inc. $2,778 19 payments
  7. ALK-Abello, Inc $2,605 8 payments
  8. Dermavant Sciences, Inc. $1,640 1 payment
  9. Pfizer Inc. $1,109 57 payments
  10. Arcutis Biotherapeutics, Inc. $1,100 1 payment
  11. Other $7,083 282 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $190,735 95 payments
  2. Consulting Fee $33,199 12 payments
  3. Food and Beverage $23,503 854 payments
  4. Travel and Lodging $6,764 30 payments
  5. Honoraria $2,400 2 payments
  6. Education $138 5 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $54,580 82 payments
  2. DUPIXENT Inflammation And Immunology $54,526 137 payments
  3. NUCALA Immunology $40,761 82 payments
  4. EBGLYSS $25,978 19 payments
  5. DUPIXENT Immunology And Inflammation $24,287 42 payments
  6. DUPIXENT Immunology $10,260 41 payments
  7. TEZSPIRE $8,203 43 payments
  8. NUCALA Respiratory $4,543 25 payments
  9. VTAMA $1,894 3 payments
  10. AREXVY $1,120 14 payments
  11. Other $13,357 538 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $8,534 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,017

Median for Allergy/ Immunology: 449

Drug cost

$1,274,911

Median for Allergy/ Immunology: $169,700

Branded share of claims

36.6%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 43 $413,747
Xolair Omalizumab Brand 121 $355,546
Dupixent Pen Dupilumab Brand 59 $217,279
Nucala Mepolizumab Brand 18 $140,048
Dupixent Syringe Dupilumab Brand 12 $51,092
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 12 $28,696
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 32 $25,111
Breo Ellipta Fluticasone/Vilanterol Brand 17 $13,210
Epinephrine Generic 36 $7,896
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 12 $7,237

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$391,112

Of which drugs: $305,455

Medicare patients

210

Average age 73

Services billed

21,798

144 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 49%
Ischemic heart disease 29%
Diabetes 23%
Depression 20%
Chronic kidney disease 17%
Osteoporosis 17%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 13 9,135 $271,607

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$35,702 71 —
NUCALA
$9,786 18 —
VTAMA
$1,640 — —
XOLAIR
$241 121 9,135
FASENRA
$214 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

1,002 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record